OraSure Technologies Stock News

The At-Home Testing Kits Market report studies extensive evaluation of the market growth predictions and restrictions. The strategies range from new product launches, expansions, agreements, joint ventures, partnerships, to acquisitions. This report comprises of a deep knowledge and information on what

CNBC's Meg Tirrell joins 'Squawk Box' to report on the increased demand for Covid-19 tests ahead of the Thanksgiving holiday.

The Drug Tester Market report is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The research analysts provide an

BETHLEHEM, Pa., Nov. 19, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analy

BETHLEHEM, Pa., Nov. 19, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR ), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will participate in a virtual fireside chat at the Stephens Annual Investment Conference on November 29, 2021 at 12:00 pm ET. Dr. Tang will also speak in a virtual fireside chat at the Evercore 4 th Annual HealthConx Virtual Conference on December 1, 2021 at 1:50 pm ET. The Full story available on Benzinga.com

BETHLEHEM, Pa., Nov. 19, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analyti

Schonfeld Strategic Advisors LLC bought a new stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 11,760 shares of the medical instruments suppliers stock, valued at approximately $119,000. Other hedge funds have also added to or reduced []

The Infectious Disease In-vitro Diagnostic Market research report is an effective tool to gain information about the markets competitive landscape by ensuing success in the global Infectious Disease In-vitro Diagnostic Market. The information and data included in the report are

Brokerages predict that OraSure Technologies, Inc. (NASDAQ:OSUR) will announce ($0.16) earnings per share for the current quarter, according to Zacks. Three analysts have issued estimates for OraSure Technologies earnings, with estimates ranging from ($0.20) to ($0.12). OraSure Technologies reported earnings of $0.03 per share during the same quarter last year, which would indicate a negative []

Cubist Systematic Strategies LLC acquired a new stake in OraSure Technologies, Inc. (NASDAQ:OSUR) in the second quarter, according to its most recent filing with the SEC. The fund acquired 107,152 shares of the medical instruments suppliers stock, valued at approximately $1,087,000. Cubist Systematic Strategies LLC owned approximately 0.15% of OraSure Technologies at the end of []

Cubist Systematic Strategies LLC bought a new position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 107,152 shares of the medical instruments suppliers stock, valued at approximately $1,087,000. Cubist Systematic Strategies LLC owned []

OraSure Technologies' (OSUR) CEO Stephen Tang on Q3 2021 Results - Earnings Call Transcript

OraSure (OSUR) delivered earnings and revenue surprises of -320.00% and 13.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

The FDA has amended OraSure Technologies Inc's (NASDAQ: OSUR) Emergency Use Authorization (EUA) for its InteliSwab COVID-19 rapid tests to only require one test for symptoms of COVID-19.  Related

BETHLEHEM, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 third quarter financial results and certain